WWARN - Worldwide Antimalarial Resistance Network

News & Media

The WWARN website offers several RSS news feeds. You can subscribe to our main news feed which includes all news items published on our website. We also offer a selection of filtered feeds, if you'd prefer to receive news relevant to one or more of our scientific modules.

Click on a feed on the right to subscribe.

17-May-2012
Following the release of the WHO strategic plan to curb the spread of insecticide resistance mosquitoes, an article in Nature News examines the challenge of resistance and the threat it poses to fragile gains in malaria control.
10-May-2012
GENEVA (9 May 2012) – A new financial forecast by the Global Fund to Fight AIDS, Tuberculosis and Malaria estimates that more than $1.6 billion in additional funding will be available in the 2012-14 period for investment in projects that save lives.  
01-May-2012
To mark World Malaria Day, the President's Malaria Initiative (PMI), led by the U.S. Agency for International Development (USAID) and implemented together with the Centers for Disease Control and Prevention (CDC), released its sixth annual report which describes the role and contributions of the U.S. Government in the effort to reduce the burden of malaria in Africa, and to monitor antimalarial drug resistance and decrease malaria transmission in the Greater Mekong Subregion.
26-April-2012
Professor Nick White, Chairman of the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand and co-author of two recent papers highlighting the increase of artemisinin resistance on the Thai-Myanmar border, describes the vital weapon to fight the malaria parasite as “more and better intelligence".
25-April-2012
Traditionally an opportunity to reflect on progress and challenges, this year’s World Malaria Day theme is Sustain Gains, Save Lives: Invest in Malaria. The recent report of artemisinin resistance on the Thai-Myanmar border is a timely reminder that significant gains – like a 30% reduction in deaths over the last decade in Africa – are fragile.
05-April-2012
Evidence that the most deadly species of malaria parasite, Plasmodium falciparum, is becoming resistant to the frontline treatment for malaria on the border of Thailand and Myanmar is reported in the ‘Lancet’ today. This increases concern that resistance could now spread to India and then Africa, as resistance to other antimalarial drugs has done before. Eliminating malaria might then prove impossible.
04-April-2012
LSHTM Research Online is a freely accessible database of the research outputs of the School. It currently holds over 19,000 bibliographic records and over 2000 full text items. These include articles, working papers, conference proceedings, reports, books and book chapters. LSHTM Research Online can be searched using keywords or browsed by author, year, faculty/department or research centre.
03-April-2012
Scientists have created unique peptide-morpholino oligomer (PMO) conjugates that penetrate red blood cells and target the molecular machinery responsible for P. falciparum parasite growth.The research was carried out by a Yale University team headed by Nobel laureate Sidney Altman following the discovery by Yale immunobiology professor Alfred Bothwell of a basic peptide that can penetrate cell walls and membranes.
03-April-2012
A recent op-ed piece by Frank Smithuis, Director of Medical Action Myanmar, and Nick White, Professor of Tropical Medicine at the Mahidol Oxford Tropical Medicine Research Unit, highlights the risk of emerging drug resistance on the Thai-Cambodia border and identify Myanmar, with the largest malaria burden in the region, as a potential conduit for the western spread of artmesinin resistance. The pair call for urgent and immediate financial support for large scale action in Myanmar to prevent the further spread of artemisinin-resistant parasites.
02-April-2012
A recent article in PLoS Medicine highlighted that malaria infections among infants can be reduced by 30 percent when antimalarial drugs are given intermittently over 12 months, according to a three-year clinical trial in Papua New Guinea.The drug regimen has been shown to effectively prevent infections by both Plasmodium falciparum and Plasmodium vivax malaria, the first among antimalarial drugs.Read the complete article at PLoS Medicine.
Syndicate content